- Experience. Mayo Clinic doctors have extensive experience and expertise in diagnosing and treating people who have atrial fibrillation and other heart rhythm disorders.
- Team approach. Mayo Clinic doctors trained in evaluating and treating heart conditions (cardiologists), doctors trained in heart surgery (cardiovascular surgeons), and other doctors work closely to evaluate and treat people who have atrial fibrillation and other heart rhythm conditions.
- Research. Mayo Clinic doctors actively conduct research in atrial fibrillation and other heart rhythm disorders and conduct clinical trials.
- Technology. Mayo Clinic doctors use the most current technology in atrial fibrillation and heart rhythm disorder treatment, including catheter radiofrequency ablation.
Mayo Clinic in Rochester, Minn., is ranked among the Best Hospitals for heart and heart surgery by U.S. News & World Report. Mayo Clinic also ranks among the Best Children's Hospitals for heart and heart surgery.
Mayo Clinic: Answers you can trust
At Mayo Clinic, we assemble a team of specialists who take the time to listen and thoroughly understand your health issues and concerns. We tailor the care you receive to your personal health care needs. You can trust our specialists to collaborate and offer you the best possible outcomes, safety and service.
Mayo Clinic is a not-for-profit medical institution that reinvests all earnings into improving medical practice, research and education. We're constantly involved in innovation and medical research, finding solutions to improve your care and quality of life. Your doctor or someone on your medical team is likely involved in research related to your condition.
Our patients tell us that the quality of their interactions, our attention to detail and the efficiency of their visits mean health care — and trusted answers — like they've never experienced.
Why Choose Mayo Clinic
What Sets Mayo Clinic Apart
Feb. 08, 2013
- Atrial fibrillation (Afib). Heart Rhythm Society. http://www.hrsonline.org/Patient-Resources/Heart-Diseases-Disorders/Atrial-Fibrillation-AFib. Accessed Dec. 19, 2012.
- Atrial fibrillation. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/af/. Accessed Dec. 19, 2012.
- Verdecchia P, et al. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE intolerant subjects with cardiovascular disease studies. Journal of Hypertension. 2012;30:1004.
- Furie KL, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: A science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:3442.
- Pradaxa prescribing information. Ridgefield, Conn.: Boehringer Ingelheim Pharmaceuticals;2012. https://www.pradaxa.com/pradaxa-prescribing-information.jsp. Accessed Dec. 19, 2012.
- Cardioversion. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/crv/. Accessed Dec. 19, 2012.
- Catheter ablation. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/ablation/. Accessed Dec. 19, 2012.
- Cheng J, et al. Surgical approaches to prevent recurrent atrial fibrillation. http://www.uptodate.com/home. Accessed Dec. 19, 2012.
- Kumar K. Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations. http://www.uptodate.com/home. Accessed Dec. 19, 2012.
- Wann LS, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;57:223.
- Xarelto (prescribing information). Titusville, N.J.: Jansen Pharmaceuticals; 2012. http://www.xareltorems.com/rems/xarelto-prescribing-information.html. Accessed Dec. 19, 2012.
- How the heart works. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/chd/heartworks.html. Accessed Dec. 19, 2012.
- FDA drug safety communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves. U.S. Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/ucm332912.htm. Accessed Dec. 27, 2012.